Kestra Medical Technologies (NASDAQ:KMTS) Earns Buy Rating from BTIG Research

Kestra Medical Technologies (NASDAQ:KMTS)‘s stock had its “buy” rating reiterated by stock analysts at BTIG Research in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $32.00 target price on the stock. BTIG Research’s price objective would suggest a potential upside of 63.60% from the stock’s current price.

A number of other research firms have also recently commented on KMTS. Piper Sandler upped their price target on shares of Kestra Medical Technologies from $27.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. The Goldman Sachs Group set a $24.00 price objective on shares of Kestra Medical Technologies in a report on Friday, January 16th. Stifel Nicolaus set a $30.00 price objective on shares of Kestra Medical Technologies in a research report on Friday, December 12th. Wells Fargo & Company upped their target price on shares of Kestra Medical Technologies from $27.00 to $28.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kestra Medical Technologies in a research report on Wednesday, December 24th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $29.00.

Kestra Medical Technologies Price Performance

Shares of KMTS stock opened at $19.56 on Wednesday. The stock has a 50 day moving average price of $24.05 and a 200 day moving average price of $24.50. Kestra Medical Technologies has a 52-week low of $13.25 and a 52-week high of $30.00. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.47 and a current ratio of 7.32. The firm has a market capitalization of $1.14 billion and a P/E ratio of -4.94.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings data on Tuesday, March 17th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.01). Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. The business had revenue of $24.55 million during the quarter. The business’s quarterly revenue was up 62.7% on a year-over-year basis.

Insider Buying and Selling at Kestra Medical Technologies

In other news, insider Traci S. Umberger sold 10,500 shares of the firm’s stock in a transaction on Monday, December 29th. The stock was sold at an average price of $26.69, for a total transaction of $280,245.00. Following the transaction, the insider owned 136,633 shares in the company, valued at approximately $3,646,734.77. This trade represents a 7.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Brian Daniel Webster sold 15,000 shares of the company’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $20.27, for a total transaction of $304,050.00. Following the completion of the sale, the insider directly owned 364,786 shares of the company’s stock, valued at approximately $7,394,212.22. This trade represents a 3.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 70,500 shares of company stock worth $1,709,145. Insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Kestra Medical Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Price T Rowe Associates Inc. MD raised its stake in Kestra Medical Technologies by 137.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock worth $115,878,000 after buying an additional 2,529,851 shares in the last quarter. Eventide Asset Management LLC boosted its position in Kestra Medical Technologies by 285.7% during the 2nd quarter. Eventide Asset Management LLC now owns 1,060,557 shares of the company’s stock valued at $17,584,000 after acquiring an additional 785,557 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of Kestra Medical Technologies by 180.8% in the 4th quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock valued at $25,221,000 after acquiring an additional 612,343 shares during the period. Millennium Management LLC purchased a new position in shares of Kestra Medical Technologies in the 1st quarter valued at $11,036,000. Finally, Brown Advisory Inc. raised its position in shares of Kestra Medical Technologies by 34.1% in the 4th quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock worth $44,775,000 after acquiring an additional 428,996 shares in the last quarter.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.